Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
WORCESTER, Mass., May 12, 2023 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (Nasdaq:MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2023.
Related news for (MBIO)
- MoBot alert highlights: NASDAQ: BMGL, NASDAQ: MBIO, NASDAQ: ENTO, NASDAQ: AQMS, NYSE: CLDI (07/09/25 06:00 AM)
- Breaking News: MoBot’s Latest Update as of 07/07/25 09:00 AM
- Market Headliners– July 7, 2025
- MoBot alert highlights: NASDAQ: MBIO, NYSE: LGPS, NASDAQ: SONN, NASDAQ: MULN, NASDAQ: CURR (07/07/25 08:00 AM)
- Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma